Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
By Maggie Fick and Ahmed Aboulenein
LONDON/WASHINGTON, July 12 (Reuters) -Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
Novo Nordisk NOVOb.CO will meet withthe aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren. In April, the lawmakerswrote to the company expressing alarm at its decision, announced in November, that it would permanently discontinue Levemir by the end of 2024.
Novo said it has given patients enough time to switch to other options, according to a May letter seen by Reuters. The company is unaware of plans for drug manufacturers to produce a biosimilar version of the insulin, the letter said, adding Novowould not assert any patent against such a version.
The sources declined to be named citing the sensitivity of the matter.
It was not clear who from Novo would attend the meeting. A company spokesperson denied there was a meeting scheduled. Shaheen, Warnock, and Warren's offices did not respond to a request for comment. Meetings between Congressional aides and company representatives are routine.
The Novo spokesperson said in a statement to Reuters on Friday that Levemir was not discontinued due to "success" of the company's newer medicinesWegovy and Ozempic, widely prescribed for weight loss and part of a new class of drugs called GLP-1 agonists.
When announcing in November the discontinuation of Levemir in the U.S.,Novo Nordisk cited manufacturing constraints, reduced patient access and available alternatives -- including its other long-acting insulin Tresiba.
The company said a number of long-acting insulins remainedon the market, but experts say it can be inconvenient and stressful for people with diabetes to change insulin regimens
Novo hasacknowledged during investor calls at quarterly earnings in the past yearthat it faces manufacturing capacity limitations for some products as it races to increase production of Wegovy and Ozempic.
The company along with rivals Eli Lilly LLY.N and Sanofi SASY.PA make 100% of all insulin sold in the U.S.
Last year all three companies agreed to cut U.S. list prices for insulin products by up to 75% in 2024, responding to political pressure to make the life-sustaining diabetes treatments more affordable.
Scrutiny of Novo has increasedat a time of record profits thanks to commercial success of Wegovy, launched in the U.S. in 2021. Sales of that weight-lossinjection propelled the company to the position of Europe's most valuable company worth 587 billion euros ($640 billion).
CEO Lars Jorgensen will testify before the Senate Committee on Health, Education, Labor and Pensions (HELP) in September on the high U.S. costs of Wegovy and Novo's diabetes drug Ozempic.
On Wednesday, Senator Bernie Sanders told Reuters he was confident that Novo can be convinced to cut prices after he publicly shamed the company over how its U.S. prices far surpass those charged in other countries.
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year.
($1 = 0.9172 euros)
($1 = 6.8419 Danish crowns)
Reporting by Maggie Fick in London and Ahmed Aboulenein in Washington; Editing by David Gregorio
免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。